Molecular recognition governs immune response. Developing highly specific binding proteins is fundamental to novel theragnostics. We develop a new molecular platform, TRACeR, for peptide-focused targeting of MHCs, with unprecedented specificity. Beyond MHC, we leverage protein generative models to address in silico antibody design. These efforts offer new insights to the immune targeting paradigm and AI modeling strategies. I will present our recent findings on the molecular and software platforms.